Mark Douglas Smith
Mark Douglas Smith's purchase track record
Mark Douglas Smith has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/15/2024 | TDOC | $28K | +26.9% | +91.4% | +10.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Barclays Raises Phreesia Price Target to $11. Barclays has raised its price target for Phreesia to $11 while maintaining an Equal-Weight rating. This update places the firm's outlook within the broader analyst consensus, which currently averages $14.13. The stock remains well below its 52-week high of $24.07, reflecting a significant drop from previous levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Teladoc Launches AI-Powered Remote Monitoring Tools. Teladoc Health has introduced new AI features that turn smartphone cameras into vital sign monitors and add ambient care tools to its Solo platform. These updates aim to strengthen the company's competitive position in digital health. While the stock has recently dipped more than the broader market, analysts maintain an average price target of $7.59, suggesting potential value relative to current levels.
Transaction History
| JAZZ | ▼ Sell | Tax Withholding | 14 | $3K | 8/31/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,692 | $408K | 8/31/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 1,605 | $0 | 8/5/2026 | View on chart |
| PHR | ▲ Buy | Grant | 19,290 | $185K | 6/24/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,157 | $267K | 6/15/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,805 | $201K | 8/8/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 3,507 | $0 | 8/7/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 7,000 | $33K | 7/2/2025 | View on chart |
| PHR | ▼ Sell | Open Market | 7,000 | $203K | 7/2/2025 | View on chart |
| PHR | ▲ Buy | Grant | 6,700 | $185K | 6/25/2025 | View on chart |
| TDOC | ▲ Buy | Open Market | 4,000 | $28K | 8/15/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,484 | $165K | 8/6/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 3,731 | $0 | 8/2/2024 | View on chart |
| PHR | ▲ Buy | Option Exercise | 7,000 | $33K | 7/18/2024 | View on chart |
| PHR | ▼ Sell | Open Market | 7,000 | $175K | 7/18/2024 | View on chart |
| PHR | ▲ Buy | Grant | 8,490 | $0 | 6/26/2024 | View on chart |
| JAZZ | ▼ Sell | Open Market | 417 | $50K | 12/4/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,241 | $171K | 8/14/2023 | View on chart |
| JAZZ | ▲ Buy | Grant | 3,075 | $0 | 8/11/2023 | View on chart |
| PHR | ▲ Buy | Grant | 6,051 | $0 | 6/28/2023 | View on chart |
| PHR | ▲ Buy | Option Exercise | 7,000 | $33K | 4/3/2023 | View on chart |
| PHR | ▼ Sell | Open Market | 6,500 | $199K | 4/3/2023 | View on chart |
| PHR | ▼ Sell | Open Market | 500 | $16K | 4/3/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 420 | $65K | 12/2/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 1,089 | $166K | 8/8/2022 | View on chart |
| JAZZ | ▲ Buy | Grant | 2,561 | $0 | 8/5/2022 | View on chart |
| PHR | ▲ Buy | Grant | 7,397 | $0 | 6/30/2022 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 819 | — | 5/17/2022 | View on chart |
| JAZZ | ▼ Sell | Open Market | 417 | $51K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.